- Conditions
- Open Angle Glaucoma
- Interventions
- Simbrinza 0.2%-1% Ophthalmic Suspension, Rocklatan 0.02%-0.005% Ophthalmic Solution, Cosopt PF 2%-0.5% Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution
- Drug
- Lead sponsor
- Prairie Eye Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Springfield, Illinois
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–3
of 3
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Normal Tension Glaucoma (NTG)
- Interventions
- QLS-101, Timolol maleate PF 0.5% ophthalmic solution
- Drug
- Lead sponsor
- Qlaris Bio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Sioux Falls, South Dakota
- Conditions
- Primary Open Angle Glaucoma, Ocular Hypertension
- Interventions
- QLS-101, Timolol Maleate
- Drug
- Lead sponsor
- Qlaris Bio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Albany, Georgia